Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the true is that ARYX is in bk but dead cat bounce we must see it here..lol
nobody belive in this stock...i yes...it will be a chapter 7 but before it filled tap the gap at 0.18..FDA is a destructor of promises....ARYX no is a promise..it has got a drug efecctive but another company like this product and FDA delayed the response...IMO
CEO is buying shares at this prices IMO
But will they hold the company together til that happens? That is why the pps is where it is.
FDA will aproval this drug in july...THEN...chachin..lol FDA retarded three consecutives..why?because this drug is effective...no more..FINAL POINT
Naronapride (ATI-7505) - Gastrointestinal Disorders
Addressing safety issues of first generation drugs
Naronapride is an oral prokinetic drug that has successfully completed Phase 2 clinical trials for the treatment of multiple gastrointestinal disorders including chronic idiopathic constipation, gastroesophageal reflux disease, or GERD, and functional dyspepsia. Naronapride was designed to have the same therapeutic benefits as cisapride, a drug marketed by Johnson & Johnson as Propulsid in the United States. Launched in 1993, cisapride reached sales of over $1.0 billion before it was withdrawn from the market in 2000 due to serious cardiovascular side effects. These side effects occurred as blood levels of the drug rose significantly when CYP450 clearance was blocked because of the presence of other drugs cleared by the same metabolic pathway. Naronapride is designed to be metabolized through the esterase pathway, eliminating metabolism through CYP450 as well as off-target cardiovascular effects. While some patients may suffer from more than one gastrointestinal disorder, it is estimated that there are more than 100 million cases of gastrointestinal disorders in the United States.
Naronapride is an orally bioavailable, small organic molecule that is a potent 5-HT4 receptor agonist that has prokinetic effects. Naronapride is highly selective, with minimal activity on the hERG channel as well as minimal to no activity at the 5-HT3 or other serotonergic receptors. This selectivity minimizes the potential for off-target pharmacological effects. The results of preclinical animal and clinical human testing to date suggest that naronapride has similar pharmacologic activity to that described in the literature for cisapride but has a substantially different metabolic and cardiac safety profile.
Gastrointestinal Disorders
Naronapride has the potential for use in various gastrointestinal disorders for which increased motility would be beneficial. Naronapride may help patients in a variety of indications including:
Chronic Constipation results from a lack of an adequate number of bowel movements over an extended period of time (usually defined as greater than six months). When suffering from chronic constipation, patients often try laxatives and fiber supplements prior to physician prescribed therapy. Due to limitations in existing treatments, a significant need exists for a safe chronic constipation therapy. It is estimated that 36 million people in the U.S. have chronic constipation and that approximately 25% of them see a physician for this condition.
IBS is a set of chronic symptoms associated with the lower gastrointestinal tract, particularly the colon, and is usually experienced as abdominal pain, bloating and discomfort. This can include constipation with difficult or painful bowel movements or diarrhea due to excess fluid in the colon. While the causes of IBS are still in question, lack of colonic motility is thought to be a primary cause. As with chronic constipation, patients need an effective motility agent when other remedies, such as change in diet, reduction of stress or consumption of laxatives or fibers, do not relieve the IBS symptoms. Naronapride is targeted for use in the segment of IBS patients who also suffer from chronic constipation. An estimated 5.5 million adults in the United States suffer from IBS with constipation while an estimated 28 million adults suffer from IBS with intermittent constipation.
Functional Dyspepsia is characterized by a number of symptoms associated with upper intestinal discomfort. In 2006, a specialist panel of clinicians issued a report entitled Rome III recommending that certain of these symptoms, including mid-to-upper abdominal discomfort characterized by postprandial fullness, early satiety or upper abdominal bloating, be classified as postprandial distress syndrome, or PDS. These symptoms are believed to be associated with deficiencies in motility of the upper gastrointestinal tract. Naronapride is being developed for the treatment of PDS. No currently marketed therapy is considered to be an optimal treatment for this condition. It is estimated that between 35 and 44 million people suffer from functional dyspepsia in the United States.
GERD is a digestive system disorder characterized by the frequent unwanted passage of stomach contents into the esophagus that result in such symptoms as heartburn and, in some cases, damage to the lining of the esophagus. Approximately $17.0 billion is spent worldwide each year on GERD and heartburn medications. Approximately 10 percent of the population experiences GERD symptoms daily. While most patients are treated with drugs that reduce the acid contents of the stomach, approximately 20 to 25 percent of patients (or 6.0 to 7.5 million people in the United States) do not obtain adequate relief from this type of treatment. This is the population that is targeted with naronapride.
Gastroparesis is a disorder of the stomach in which contents from the stomach do not move efficiently into the small intestine. The digestive system, including the stomach, uses muscular contractions to move its contents along the gastrointestinal tract. Gastroparesis results when there is some damage or malfunction to this process in the stomach, resulting in symptoms such as nausea and vomiting, severe abdominal pain, bacterial infections and weight loss. Diabetics are particularly susceptible to this condition. It is estimated that approximately five million patients suffer from gastroparesis in the United States. No existing therapies adequately meet this patient need.
Naronapride Development Status
More than 900 subjects have been treated with naronapride in clinical trials, including three Phase 2 trials. In these trials, dosing with naronapride showed efficacy in both lower and upper GI indications. In a Phase 2b study, naronapride demonstrated statistical significance (80 mg BID) in the improvement of chronic idiopathic constipation. In earlier Phase 2 studies, naronapride demonstrated its potential in the upper GI tract by showing a reduction in acid reflux, and in some measurements of nighttime heartburn, nighttime acid regurgitation, and multiple functional dyspepsia symptoms, as well as a dose-related increase in GERD erosion healing rates in patients with less severe erosions. In addition, we have shown statistically significant improvement in some measures of both upper and lower gastrointestinal motility in healthy volunteers. Based upon the data generated in these clinical trials, a Phase 2 study also was initiated in patients with chronic constipation.
A Thorough QT (TQT) study, testing the cardiac safety of naronapride, has also been completed. Those results confirmed the earlier safety profile of naronapride by showing the compound does not significantly affect the QT interval at either therapeutic or supratherapeutic doses.
doji on weekly chart...This week could be monsta for ARYX...fda decisition on few weeks..a drug on PHASE III REMEMBER GUYS!!!
i agree ARYX may be has got a worse horse weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
I hear ya, I've bet on worse horses.
some people think that fda finally will aproval drug about gastrointestinal disseases...i am buying at this prices...
Held up fairly well considering the Form 25 came out today, but it wasn't exactly a surprise.
Depends on how you read the wind down news from yesterday.
Am I wrong, or is this a great long term buying opportunity?
Goodnight ARYX, thank you FDA for destroying a company with promising products.
I guess its good news that they haven't declared bankruptcy yet, but had been hoping they would go to the OTC to really make the pps drop. Don't think its gonna work out, and these pps levels are too high to play spec on when they have no employees and no money.
SYNARC -
http://www.synarc.com
Possible Partnership
Also FDA - approval expected first of yr. for Phase III
I think we will see a gap up at the opening tomorrow...bid x ask after hours is 0.40 x 0.41.
Two drugs with issues - possible Aryx opportunity,Merck and Sanofi recently announced problems with two drugs and both with possible positive implications for the Aryx portfolio.
Merck: Merck shares fell after the company said it discontinued a clinical trial of an anti-clotting drug that was a prominent part of the company’s pipeline and was likely to be submitted for marketing approval this year.The company also said it reduced the size of another trial of the same drug, vorapaxar.
Sanofi:Associated Press - Jan. 14, 2011
WASHINGTON -- Federal health officials are warning doctors and patients that a recently launched heart drug from Sanofi-Aventis SA is linked to liver damage in a handful of U.S. patients.
The Food and Drug Administration said it has received several reports of liver damage with Multaq tablets, including two cases in which patients had had to have their livers removed.
The FDA approved Multaq in 2009 to treat atrial flutter and atrial fibrillation, which are irregular heart rhythms that can reduce blood flow and lead to stroke.
Looks like good news on it's way this will see over $2!
Yes I love me some DIMEQ.
Looks like this stock is doing OK, send me a message if it drops and I'll help make it bounce with ya.
And still buying DIMEQ. LOL
I am pretty disappointed this has not gone down to retest the PM lows around .14 the day they put the bad news out..I was hoping to scrape up several thousand under .10
ARYX will be green this week
We might see a big move up buying Monday!What I've heard Something big is coming. So expect bashers out in much larger forces this coming weeks.Good luck!
Awesome movement here! Nicely done into EOD...looking for a pop in the early morning. hopefully we can see .35 at close tomorrow...
Nice little bounce. Trade em don't marry em! Ho Ho Ho!
volume coming in...
up .28, nice...
I jumped out yesterday to buy some DIMEQ. (LOL)
Zilla, I think they will be delisted, so your hope for another TTNP may be in play.
Wedbush sure doesnt think that ARYX is a scam, they just say they need money.
Why do you keep calling this a scam company? It is nothing of the sort, they simply have run out of money and had to lay the entire staff off because the FDA is not being timely in getting back to them with an SPA agreement for a phase 3 trial. If the FDA would do their job on time ARYX may not be in this position right now and instead would be getting ready to start a trial.
Oh jeez...look who's in here now...the big money's rolling in
Another new 52-week low $0.17 was created today! Sell this pos scam ASAP before the possible CH11 filing. Huge dilution then R/S game.
hmm... not sure... on watch...
Yeah it's been an interesting morning. .24 High and the MM's we're stepping over each other at first. Don't know why but I'm green already and didn't get faked out on Friday.
do you see this climbing more? down to .2142 as i type this message
up more... .23 so far...
I'm not pumping. (LOL) Reread the post and see all the bad things I said COULD happen. Pumpers wear rose colored glasses I do not. I did compare it to TTNP but it hasn't done what they did. It means it's not over. I said I'm not selling it and planning on getting more at .10, .05 and every penny down from there. If it doesn't get that low then I hold and see where we're going.
BK stocks go up all the time, but if you KNOW the shares will be wiped, well then you're trying to get bag holders in so you can get out IMO.
Another new 52-week low $0.1715 was created today! Sell the pos scam ASAP before it is too late (possible CH11 filing). By the way WLVTQ
is up 14.3% today with big volume (near 600K shares). You pump ARYX?
Another new 52-week low $0.173 was created today! Sell the pos scam ASAP before it hits another new low $0.17 or $0.16. Glad to short it
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
219
|
Created
|
11/07/07
|
Type
|
Free
|
Moderators |
Important recent 8k
Item 2.04. Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.
On March 16, 2011, we received a notice of default, or the Notice, from Lighthouse Capital Partners V, L.P., or Lighthouse, indicating that an event of default occurred under that certain Loan and Security Agreement No. 4512, dated as of March 28, 2005, as amended, by and between Lighthouse and us, or the Loan Agreement.
The Notice was the result of our failure to make scheduled payments due under the Loan Agreement for the period from December 1, 2010 through March 1, 2011 and the winding down of our operations, each of which constitutes a material breach of our obligations under the Loan Agreement. Accordingly, as set forth in the Notice, an event of default has occurred under Sections 8.1 and 8.2 of the Loan Agreement.
In connection with the Loan Agreement, we granted Lighthouse a security interest in our assets, including our intellectual property, or the Collateral. In accordance with Section 9.1 of the Loan Agreement, the Notice demands we turn over all Collateral covered by the Loan Agreement to Lighthouse, including cash Collateral, and cease any future use of cash Collateral. We may not be able to make the payments required under the Loan Agreement, and, as previously disclosed, are currently in discussions with Lighthouse and our other secured creditors to facilitate an orderly disposition of our assets. However, there is no assurance we will reach any agreement with Lighthouse and, in such event, our assets may be subject to foreclosure and seizure by Lighthouse under the terms of the Loan Agreement. We are also considering other alternatives, including filing a bankruptcy petition under Chapter 7 of the U.S. Bankruptcy Code.
http://www.aryx.com/
http://www.aryx.com/wt/page/products
http://finance.yahoo.com/q/h?s=ARYX
ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. The company's products in Phase II clinical trials include ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of patients with atrial fibrillation. Its preclinical development stage product comprises ATI-9242 for the treatment of schizophrenia and other psychiatric disorders. In addition, the company's late stage discovery programs consist of ATI-20,000 and ATI-24,000, which focuses on metabolic and gastrointestinal disorders. ARYx Therapeutics has collaboration agreement with Procter & Gamble Pharmaceuticals, Inc. for the development and commercialization of ATI-7505. The company was incorporated in 1997 and is based in Fremont, California.
ARYx Therapeutics Clarifies Current Status of Operations |
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today provided further clarification of its status as an operating company, including the on-going appointment of its officers on behalf of the Company. The NASDAQ Staff has requested additional clarification about the Company’s operations in conjunction with their on-going consideration of the Company’s eligibility for continued listing on The NASDAQ Capital market. ARYx remains operational, with specific activities underway, which are designed to further the development and approval of naronapride, and to enhance the value of the Company’s assets. In addition, four officers of ARYx remain in their respective roles as officers, appointed by the board of directors to operate the company in good standing. The officers’ duties, as specified in the ARYx Charter, remain unchanged by the recent reorganization, including the change in their compensation methodology. As previously announced, ARYx has substantially reduced its operating expenses as the Company awaits guidance from the Food and Drug Administration (“FDA”) on the continued development of its product candidate for various gastrointestinal disorders, naronapride (see press releases of December 15, 2010 and December 21, 2010). Notwithstanding this reduction in operating costs, important functions remain operational and are performed by the Company’s officers and by those former employees of ARYx who, as of December 15, 2010, are now providing needed services under executed consulting agreements. These activities include: regular, current communications with the FDA on matters related to the continued development of naronapride; maintenance of drug product necessary to execute the planned Phase 3 clinical trials on naronapride; maintenance of the 44,000 square foot facility housing ARYx, including the substantial equipment; active consultation with leading physicians and others about the continued development of naronapride in anticipation of FDA guidance; management of due diligence for those current and potential investors involved in the potential continued funding of the ARYx operations; and, the functioning of the Finance group. While the Company is working toward regaining compliance with all applicable NASDAQ listing requirements, there can be no assurance that it will be able to do so or that its securities will continue to remain listed on The NASDAQ Stock Market. In addition, there is no assurance ARYx will be able to obtain necessary agreements from its secured creditors and the additional funding from investors needed to continue operations beyond 2010 and through to the receipt of the anticipated FDA guidance. |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |